دورية أكاديمية
Radiographical Evaluation of Tumor Immunosuppressive Microenvironment and Treatment Outcomes in Gastric Cancer: A Retrospective, Multicohort Study.
| العنوان: | Radiographical Evaluation of Tumor Immunosuppressive Microenvironment and Treatment Outcomes in Gastric Cancer: A Retrospective, Multicohort Study. |
|---|---|
| المؤلفون: | Lin JX; Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou,, Fujian Province, China.; Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian Province, China.; Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China., Lin JP; Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou,, Fujian Province, China.; Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian Province, China.; Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China., Weng Y; Department of Gastrointestinal Surgery, Affiliated Hospital of Qinghai University, Xining, Qinghai Province, China., Lv CB; Department of General Surgery, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian Province, China., Chen JH; Department of Radiology, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China., Zhan CY; Department of Radiology, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China., Li P; Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou,, Fujian Province, China.; Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian Province, China.; Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China., Xie JW; Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou,, Fujian Province, China.; Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian Province, China.; Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China., Wang JB; Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou,, Fujian Province, China.; Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian Province, China.; Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China., Lu J; Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou,, Fujian Province, China.; Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian Province, China.; Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China., Chen QY; Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou,, Fujian Province, China.; Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian Province, China.; Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China., Cao LL; Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou,, Fujian Province, China.; Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian Province, China.; Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China., Lin M; Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou,, Fujian Province, China.; Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian Province, China.; Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China., Zhou WX; Department of Gastrointestinal Surgery, Affiliated Hospital of Qinghai University, Xining, Qinghai Province, China., Zhang XJ; Department of Gastrointestinal Surgery, Affiliated Hospital of Qinghai University, Xining, Qinghai Province, China., Zheng CH; Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou,, Fujian Province, China.; Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian Province, China.; Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China., Cai LS; Department of General Surgery, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian Province, China., Ma YB; Department of Gastrointestinal Surgery, Affiliated Hospital of Qinghai University, Xining, Qinghai Province, China., Huang CM; Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou,, Fujian Province, China. hcmlr2002@163.com.; Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian Province, China. hcmlr2002@163.com.; Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China. hcmlr2002@163.com. |
| المصدر: | Annals of surgical oncology [Ann Surg Oncol] 2022 Aug; Vol. 29 (8), pp. 5022-5033. Date of Electronic Publication: 2022 Mar 16. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Country of Publication: United States NLM ID: 9420840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-4681 (Electronic) Linking ISSN: 10689265 NLM ISO Abbreviation: Ann Surg Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2005- : New York, NY : Springer Original Publication: New York, NY : Raven Press, c1994- |
| مواضيع طبية MeSH: | Epstein-Barr Virus Infections*/pathology , Stomach Neoplasms*/diagnostic imaging , Stomach Neoplasms*/drug therapy, Herpesvirus 4, Human ; Humans ; Neoplasm Staging ; Prognosis ; Retrospective Studies ; Treatment Outcome ; Tumor Microenvironment |
| مستخلص: | Background: The tumor immunosuppressive microenvironment can influence treatment response and outcomes. A previously validated immunosuppression scoring system (ISS) assesses multiple immune checkpoints in gastric cancer (GC) using tissue-based assays. We aimed to develop a radiological signature for non-invasive assessment of ISS and treatment outcomes. Methods: A total of 642 patients with resectable GC from three centers were divided into four cohorts. Radiomic features were extracted from portal venous-phase CT images of GC. A radiomic signature for predicting ISS (RISS) was constructed using the least absolute shrinkage and selection operator (LASSO) regression method. Moreover, we investigated the value of the RISS in predicting survival and chemotherapy response. Results: The RISS, which consisted of 10 selected features, showed good discrimination of immunosuppressive status in three independent cohorts (area under the curve = 0.840, 0.809, and 0.843, respectively). Multivariate analysis revealed that the RISS was an independent prognostic factor for both disease-free survival (DFS) and overall survival (OS) in all cohorts (all p < 0.05). Further analysis revealed that stage II and III GC patients with low RISS exhibited a favorable response to adjuvant chemotherapy (OS: hazard ratio [HR] 0.407, 95% confidence interval [CI] 0.284-0.584); DFS: HR 0.395, 95% CI 0.275-0.568). Furthermore, the RISS could predict prognosis and select stage II and III GC patients who could benefit from adjuvant chemotherapy independent of microsatellite instability status and Epstein-Barr virus status. Conclusion: The new, non-invasive radiomic signature could effectively predict the immunosuppressive status and prognosis of GC. Moreover, the RISS could help identify stage II and III GC patients most likely to benefit from adjuvant chemotherapy and avoid overtreatment. (© 2022. Society of Surgical Oncology.) |
| التعليقات: | Comment in: Ann Surg Oncol. 2022 Aug;29(8):5034-5035. (PMID: 35543909) |
| References: | Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. (PMID: 2771884710.1056/NEJMoa1606774) Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;26:2521–32. (PMID: 10.1056/NEJMoa1503093) Huber V, Camisaschi C, Berzi A, et al. Cancer acidity: an ultimate frontier of tumor immune escape and a novel target of immunomodulation. Semin Cancer Biol. 2017;43:74–89. (PMID: 2826758710.1016/j.semcancer.2017.03.001) Toor SM, Sasidharan Nair V, Decock J, Elkord E. Immune checkpoints in the tumor microenvironment. Semin Cancer Biol. 2020;65:1–12. (PMID: 3126589310.1016/j.semcancer.2019.06.021) Wang JB, Li P, Liu XL, et al. An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer. Nat Commun. 2020;1:6352. (PMID: 10.1038/s41467-020-20260-7) Mu W, Jiang L, Zhang J, et al. Non-invasive decision support for NSCLC treatment using PET/CT radiomics. Nat Commun. 2020;1:5228. (PMID: 10.1038/s41467-020-19116-x) Du Y, Qi Y, Jin Z, Tian J. Noninvasive imaging in cancer immunotherapy: the way to precision medicine. Cancer Lett. 2019;466:13–22. (PMID: 3149911910.1016/j.canlet.2019.08.009) Limkin EJ, Sun R, Dercle L, et al. Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology. Ann Oncol. 2017;6:1191–206. (PMID: 10.1093/annonc/mdx034) Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;12:749–62. (PMID: 10.1038/nrclinonc.2017.141) Ajani JA, D’Amico TA, Almhanna K, et al. Gastric cancer, version 3. 2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;10:1286–312. (PMID: 10.6004/jnccn.2016.0137) Sun R, Limkin EJ, Vakalopoulou M, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 Or anti-PD-L1 immunotherapy: an imaging biomarker retrospective multicohort study. Lancet Oncol. 2018;9:1180–91. (PMID: 10.1016/S1470-2045(18)30413-3) Jiang Y, Wang H, Wu J, et al. Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer. Ann Oncol. 2020;31(6):760–8. (PMID: 3224079410.1016/j.annonc.2020.03.295) Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;2:87–108. (PMID: 10.3322/caac.21262) Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;12:1389–96. (PMID: 10.1016/S1470-2045(14)70473-5) Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO clinical practice guidelines for diagnosis treatment and follow-up. Ann Oncol. 2016;27(Suppl 5):v38-49. (PMID: 2766426010.1093/annonc/mdw350) Jiang Y, Li T, Liang X, et al. Association of adjuvant chemotherapy with survival in patients with stage II or III gastric cancer. JAMA Surg. 2017;7:e171087. (PMID: 10.1001/jamasurg.2017.1087) Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011;3:151–60. (PMID: 10.1038/nrclinonc.2010.223) Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II Or III gastric cancer. J Clin Oncol. 2011;33:4387–93. (PMID: 10.1200/JCO.2011.36.5908) Amin MB, Edge SB. AJCC Cancer Staging Manual. 8th edn. New York: Springer; 2016. Tibshirani R. Regression shrinkage and selection via the lasso: a retrospective. J R Stat Soc Series B (Stat Methodol). 2011;3:267–88. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B (Stat Methodol). 1995;57(1):289–300. Wang YQ, Zhang Y, Jiang W, et al. Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis. J Immunother Cancer. 2019;7:298. (PMID: 31722750685470610.1186/s40425-019-0752-4) Parra ER, Villalobos P, Zhang J, et al. Immunohistochemical and image analysis-based study shows that several immune checkpoints are co-expressed in non-small cell lung carcinoma tumors. J Thorac Oncol. 2018;6:779–91. (PMID: 10.1016/j.jtho.2018.03.002) Pardoll DM. Immunology beats cancer: a blueprint for successful translation. Nat Immunol. 2012;12:1129–32. (PMID: 10.1038/ni.2392) Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;3:239–45. (PMID: 10.1038/ni1443) Lam KK, Chiu PC, Lee CL, et al. Glycodelin-A protein interacts with siglec-6 protein to suppress trophoblast invasiveness by down-regulating extracellular signal-regulated kinase (ERK)/c-Jun signaling pathway. J Biol Chem. 2011;43:37118–27. (PMID: 10.1074/jbc.M111.233841) Paiva B, Corchete LA, Vidriales MB, et al. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood. 2016;127(15):1896–906. (PMID: 2675571110.1182/blood-2015-08-665679) Gromeier M, Nair SK. Recombinant poliovirus for cancer immunotherapy. Annu Rev Med. 2018;69:289–99. (PMID: 29414253601383610.1146/annurev-med-050715-104655) Ding W, Shimada H, Li L, et al. Retinoid agonist Am 80-enhanced neutrophil bactericidal activity arising from granulopoiesis in vitro and in a neutropenic mouse model. Blood. 2013;6:996–1007. (PMID: 10.1182/blood-2012-06-436022) Ladoire S, Enot D, Senovilla L, et al. The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. Autophagy. 2016;5:864–75. (PMID: 10.1080/15548627.2016.1154244) Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020;8:e000957. (PMID: 32900861747796810.1136/jitc-2020-000957) Herskind C, Talbot CJ, Kerns SL, Veldwijk MR, Rosenstein BS, West CM. Radiogenomics: a systems biology approach to understanding genetic risk factors for radiotherapy toxicity? Cancer Lett. 2016;1:95–109. (PMID: 10.1016/j.canlet.2016.02.035) Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;5:646–74. (PMID: 10.1016/j.cell.2011.02.013) Gourzones C, Barjon C, Busson P. Host-tumor interactions in nasopharyngeal carcinomas. Semin Cancer Biol. 2012;2:127–36. (PMID: 10.1016/j.semcancer.2012.01.002) Ji GW, Zhu FP, Xu Q, et al. Radiomic features at contrast-enhanced CT predict recurrence in early stage hepatocellular carcinoma: a multi-institutional study. Radiology. 2020;3:568–79. (PMID: 10.1148/radiol.2020191470) Colen RR, Rolfo C, Ak M, et al. Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer. 2021;9(4):e001752. (PMID: 33849924805140510.1136/jitc-2020-001752) Velazquez ER, Parmar C, Jermoumi M, et al. Volumetric CT-based segmentation of NSCLC using 3D-slicer. Sci Rep. 2013;3:3529. (PMID: 24346241386663210.1038/srep03529) McLean MH, El-Omar EM. Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol. 2014;11:664–74. (PMID: 2513451110.1038/nrgastro.2014.143) Razzak M. Genetics: new molecular classification of gastric adenocarcinoma proposed by the cancer genome atlas. Nat Rev Clin Oncol. 2014;9:499. (PMID: 10.1038/nrclinonc.2014.138) Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label randomised controlled trial. Lancet. 2012;9813:315–21. (PMID: 10.1016/S0140-6736(11)61873-4) Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;17:1729–37. Nishida T. Adjuvant therapy for gastric cancer after D2 gastrectomy. Lancet. 2012;9813:291–2. (PMID: 10.1016/S0140-6736(11)61928-4) Coffelt SB, de Visser KE. Immune-mediated mechanisms influencing the efficacy of anticancer therapies. Trends Immunol. 2015;4:198–216. (PMID: 10.1016/j.it.2015.02.006) Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;6:690–714. (PMID: 10.1016/j.ccell.2015.10.012) Lin JP, Zhao YJ, He QL, et al. Adjuvant chemotherapy for patients with gastric neuroendocrine carcinomas or mixed adenoneuroendocrine carcinomas. Br J Surg. 2020;9:1163–70. (PMID: 10.1002/bjs.11608) Akce M, Jiang R, Alese OB, et al. Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a national cancer database (ncdb) analysis. J Gastrointest Oncol. 2019;1:85–94. Nowak AK, Lesterhuis WJ, Kok PS, et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (dream): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 2020;9:1213–23. (PMID: 10.1016/S1470-2045(20)30462-9) Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9. (PMID: 10.1038/nature13480) Tan P, Yeoh KG. Genetics and molecular pathogenesis of gastric adenocarcinoma. Gastroenterology. 2015;149(5):1153–62. (PMID: 2607337510.1053/j.gastro.2015.05.059) Pietrantonio F, Miceli R, Raimondi A, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol. 2019;37(35):3392–400. (PMID: 3151348410.1200/JCO.19.01124) |
| معلومات مُعتمدة: | 2019Y9098 Joint Funds for the Innovation of Science and Technology, Fujian province |
| تواريخ الأحداث: | Date Created: 20220316 Date Completed: 20220706 Latest Revision: 20220706 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1245/s10434-022-11499-z |
| PMID: | 35294651 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1534-4681 |
|---|---|
| DOI: | 10.1245/s10434-022-11499-z |